Monitoring of neuromuscular blocking;Monitorización del bloqueo neuromuscular

Medicina Intensiva

Volumn 32, Issue SUPPL. 1, 2008, Pages 53-58

  Chamorro Jambrina, C ^a   Silva, J A ^b  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE CIUDAD REAL   (Spain)

Author keywords

Bispectral index; Critically ill patient; Facial nerve; Mechanical ventilation; Monitoring; Neuromuscular blockers; Protocols; Residual paralysis; Train of four; Ulnar nerve

Indexed keywords

CREATINE KINASE; NEUROMUSCULAR BLOCKING AGENT;

ADDUCTOR POLLICIS MUSCLE; ANALGESIA; ARTIFICIAL VENTILATION; BISPECTRAL INDEX; CLINICAL PROTOCOL; CRITICALLY ILL PATIENT; DRUG DOSE REGIMEN; DRUG EFFICACY; EMOTIONAL STRESS; EXTUBATION; FACIAL NERVE; HAND MUSCLE; HUMAN; MENTAL STRESS; NERVE STIMULATION; NEUROMUSCULAR BLOCKING; PARALYSIS; PATIENT MONITORING; REVIEW; SEDATION; ULNAR NERVE; VEIN THROMBOSIS;

ANESTHESIA, GENERAL; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY; ELECTRIC STIMULATION; FACIAL NERVE; HUMANS; MONITORING, PHYSIOLOGIC; NEUROMUSCULAR BLOCKING AGENTS; ULNAR NERVE;

EID: 45749085789     PISSN: 02105691     EISSN: 15786749     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. Hansen-Flaschen JH, Brazinsky S, Basile C, Lanken PN. Use of sedating drugs and neuromuscular blocking agents in patients requiring mechanical ventilation for respiratory failure: a national survey. JAMA. 1991;266:2870-6.
2. Appadu BL, Greiff JMC, Thompson JP. Postal survey on the long-term use of neuromuscular block in the intensive care. Intensive Care Med. 1996;22:862-6.
3. Isenstein DA, Venner DS, Duggan J. Neuromuscular blockade in the intensive care unit. Chest. 1992;102:1258-66.
4. Viby-Mogensen J. Monitoring neuromuscular function in the intensive care unit. Intensive Care Med. 1993;19 Suppl 2:S74-9.
5. Dulin PG, Williams CJ. Monitoring and preventive care of the paralyzed patient in respiratory failure. Crit Care Clin. 1994;10:815-26.
6. Lewis KS, Rothenberg DM. Neuromuscular blockade in the intensive care unit. Am J Health Syst Pharm. 1999;56:72-5.
7. Gehr LC, Sessler CN. Neuromuscular blockade in the intensive care unit. Semin Respir Crit Care Med. 2001;22:175-88.
8. Murphy GS, Vender JS. Neuromuscular-blocking drugs. Critical Care Clin. 2001;17:925-42.
9. Riker RR, Fraser GL. Monitoring sedation, agitation, analgesia, neuromuscular blockade, and delirium in adult ICU patients. Semin Respir Crit Care. 2001;22:189-98.
10. Murray MJ, Cowen J, DeBlock H, Erstad B, Gray AW, Tescher AN, et al. Clinical practice guidelines for sustained neuromuscular blockade in the adult critically ill patient. Crit Care Med. 2002;30:142-56.
11. Sessler CN. Train-of-four to monitor neuromuscular blockade? Chest. 2004;126:1019-22.
12. Estecha MA, De La Cruz CA, Chamorro C, Romera MA. Uso racional de los bloqueantes neuromusculares en la unidad de cuidados intensivos. Med Intensiva. 1995;19:371-8.
13. Chamorro C, Romera MA, Rubio JJ. Ensayos clínicos sobre bloqueantes neuromusculares en pacientes críticos. En: de la Torre FJ, editor. El ensayo clínico en medicina intensiva. Madrid: Ediciones Ergon; 1997. p. 69-96.
14. Brull SJ. An update on monitoring of neuromuscular function. Curr Op Aneasth. 1992;5:577-83.
15. Hemmerling TM, Le N. Neuromuscular monitoring: an update for the clinician. Can J Anesth. 2007;54:58-72.
16. Rudis MI, Guslist BG, Zarowitz BJ. Technical and interpretive problems of peripheral nerve stimulation in monitoring neuromuscular blockade in the intensive care unit. Ann Pharmacother. 1996;30:165-72.
17. Lagneau F, Benayoun L, Plaud B, Bonnet F, Favier J, Marty J. The interpretation of train-of-four monitoring in intensive care: what about the muscle site and the current intensity. Intensive Care Med. 2001;27:1058-63.
18. Harper NJ, Greer R, Conway D. Neuromuscular monitoring in intensive care patients: milliamperage requirements for supramaximal stimulation. Br J Anaesth. 2001;87:625-7.
19. Drenck NE, Ueda N, Olsen NV, Engbaek J, Jensen E, Skovgaard LT, et al. Manual evaluation of residual curarization using double burst stimulation: a comparison with train-of-four. Anesthesiology. 1989;70:578-81.
20. Braude N, Vyvyan HAL, Jordan MJ. Intraoperative assessment of atracurium-induced neuromuscular block using double burst estimulation. Br J Anaesth. 1991;67:574-8.
21. Loan PB, Paxton LD, Mirakhur RK, Connolly FM, McCoy EP. The TOF-Guard neuromuscular transmission monitor. A comparison with the Myograph 2000. Anaesthesia. 1995;50:699-702.
22. Segredo V, Caldwell JE, Matthay MA, Sharma ML, Gruenke LD, Miller RD. Persistent paralysis in critically ill patients after long-term administration of vecuronium. N Engl J Med. 1992;327:524-8.
23. Watling SM, Dasta JF. Prolonged paralysis in intensive care unit patients after the use of neuromuscular blocking agents: A review of the literature. Crit Care Med. 1994;22:884-93.
24. Rudis MI, Sikora CA, Angus E, Peterson E, Popovich J Jr, Hyzy R, et al. A prospective, randomized, controlled evaluation of peripheral nerve stimulation versus standard clinical dosing of neuromuscular blocking agents in critically ill patients. Crit Care Med. 1997;25:575-83.
25. Strange C, Vaughan L, Franklin C, Johnson J. Comparison of train-of-four and best clinical assessment during continuous paralysis. Am J Respir Crit Care Med. 1997;156:1556-61.
26. Baumann MH, McAlpin W, Brown K, Patel P, Ahmad I, Stewart R, et al. A prospective randomized comparison of train-offour monitoring and clinical assessment during continuous ICU cisatracurium paralysis. Chest. 2004;126:1267-73.
27. Zarowitz BJ, Rudis MI, Lai K, Petitta A, Lulek M. Retrospective pharmacoeconomic evaluation of dosing vecuronium by peripheral nerve stimulation versus standard clinical assessment in critically ill patients. Pharmacotherapy. 1997;17:327-32.
28. Danon MJ, Carpenter S. Myopathy with thick filament (myosin) loss following prolonged paralysis with vecuronium during steroid treatment. Muscle Nerve. 1991;14:1131-9.
29. Rich MM, Teener JW, Raps EC, Schotland DL, Bird SJ. Muscle is electrically inexcitable in acute quadriplegic myopathy. Neurology. 1996;46:731-6.
30. Khuenl-Brady KS, Reitstatter B, Schlager A, Schreithofer D, Luger T, Seyr M, et al. Long-term administration of pancuronium and pipecuronium in the intensive care unit. Anesth Analg. 1994;78:1082-6.
31. Frankel H, Jeng J, Tilly E, Andre AS, Champion H. The impact of implementation of neuromuscular blockade monitoring standards in a surgical intensive care unit. Am Surg. 1996;62:503-6.
32. Mascia MF, Koch M, Medicis JJ. Pharmacoeconomic impact of rational use guidelines on the provision of analgesia, sedation, and neuromuscular blockade in critical care. Crit Care Med. 2000;28:2300-6.
33. Jones SK. An algorithm for train-of-four monitoring in patients receiving continous neuromuscular blocking agents. Dimens Crit Care Nurs. 2003;22:50-7.
34. Lagneau F, D'honneur G, Plaud B, Mantz J, Gillart T, Duvaldestin P, et al. A comparison of two depths of prolonged neuromuscular blockade induced by cisatracurium in mechanically ventilated critically ill patients. Intensive Care Med. 2002;28:1735-41.
35. Ellender PJ. The use of neuromuscular blocking agents in the ICU patients. Hosp Pharm. 1994;29:36-44.
36. Prielipp RC, Coursin DB, Scuderi PE, Bowton DL, Ford SR, Cardenas VJ, et al. Comparison of the infusion requirements and recovery profiles of vecuronium and cisatracurium 51W89 in intensive care unit patients. Anesth Analg. 1995;81:3-12.
37. Pearson AJ, Harper NJN, Pollard BJ. The infusion requirements and recovery characteristics of cisatracurium or atracurium in intensive care patients. Intensive Care Med. 1996;22:694-8.
38. Hodges UM. Vecuronium infusions requirements in paediatric patients in intensive care units: the use of acceleromyography. Br J Anaesth. 1996;76:23-8.
39. Fiamengo SA, Savarese JJ. Use of muscle relaxants in intensive care units. Crit Care Med. 1991;19:1457-9.
40. Chamorro C, Romera MA, Borrallo JM, Ruiz de Luna R, Melgar JL, Estecha MA. Nivel mínimo de bloqueo neuromuscular en pacientes críticos durante el uso de bloqueantes neuromusculares. Med Intensiva. 1996;20 Supl 1:347A.
41. Werba A, Klezl M, Schramm W, Langenecker S, Müller C, Gosch M, et al. The level of neuromuscular block needed to suppress diaphragmatic movement during tracheal suction in patients with raised intracranial pressure: a study with vecuronium and atracurium. Anaesthesia. 1993;48:301-3.
42. Viby-Mogensen J, Jorgensen BC, Ording H. Residual curarization in the recovery room. Anesthesiology. 1979;50:539-41.
43. Viby-Mogensen J. Postoperative residual curarization and evidence-based anaesthesia. Br J Anaesth. 2000;84:301-3.
44. Murphy GS. Residual neuromuscular blockade: incidence, assessment, and relevance in the postoperative period. Minerva Anestesiol. 2006;72:97-109.
45. Berg H, Roed J, Viby-Mogensen J, Mortensen CR, Engbaek J, Skovgaard LT, et al. Residual neuromuscular block is a risk factor for postoperative pulmonary complications. A prospective, randomised, and blinded study of postoperative pulmonary complications after atracurium, vecuronium and pancuronium. Acta Anaesthesiol Scand. 1997;41:1095-103.
46. Eriksson LI, Sundman E, Olsson R, Nilsson L, Witt H, Ekberg O, et al. Functional assessment of the pharynx at rest and during swallowing in partially paralyzed humans: simultaneous videomanometry and mechanomyography of awake human volunteers. Anesthesiology. 1997;87:1035-43.
47. Eriksson LI, Sato M, Severinghaus JW. Effect of a vecuronium-induced partial neuromuscular block on hypoxic ventilatory response. Anesthesiology. 1993;78:693-9.
48. Sundman E, Witt H, Olsson R, Ekberg O, Kuylenstierna R, Eriksson LI. The incidence and mechanisms of pharyngeal and upper esophageal dysfunction in partially paralyzed humans: pharyngeal videoradiography and simultaneous manometry after atracurium. Anesthesiology. 2000;92:977-84.
49. Baillard C, Gehan G, Reboul-Marty J, Larmignat P, Samama CM, Cupa M. Residual curarization in the recovery room after vecuronium. Br J Anaesth. 2000;84:394-5.
50. Debaene B, Plaud B, Dilly MP, Donati F. Residual paralysis in the PACU after a single intubating dose of nondepolarizing muscle relaxant with an intermediate duration of action. Anesthesiology. 2003;98:1042-8.
51. Hayes AH, Mirakhur RK, Breslin DS, Reid JE, McCourt KC. Postoperative residual block after intermediate-acting neuromuscular blocking drugs. Anaesthesia. 2001;56:312-8.
52. Fruergaard K, Viby-Mogensen J, Berg H, el-Mahdy AM. Tactile evaluation of the response to double burst stimulation decreases, but does not eliminate, the problem of postoperative residual paralysis. Acta Anaesthesiol Scand. 1998;42:1168-74.
53. Wagner BK, Zavotsky KE, Sweeney JB, Palmeri BA, Hammond JS. Patient recall of therapeutic paralysis in a surgical critical care unit. Pharmacotherapy. 1998;18:358-63.
54. Hardin KA, Seyal M, Stewart T, Bonekat HW. Sleep in critically ill chemically paralyzed patients requiring mechanical. Chest. 2006;129:1468-77.
55. Kaplan L, Bailey H. Bispectral (BIS) monitoring of ICU patients on continuous infusions of sedatives and paralytics reduces sedative drug utilitation and cost. Crit Care. 2000;4:S110.
56. Chamorro C, Martínez-Melgar JL, Barrientos R, Grupo de Trabajo de Analgesia y Sedación de la SEMICYUC. Monitorización de la sedación. Med Intensiva. 2008;32:Supl 1:45-52.
57. Davidson JE. Neuromuscular blockade: Indications, peripheral nerve stimulation, and other concurrent interventions. New Horiz. 1994;2:75-84.
58. Pino RM. Neuromuscular blocker studies of critically ill patients. Intensive Care Med. 2002;28:1695-7.
59. Douglass JA, Tuxen DV, Horne M, Scheinkestel CD, Weinmann M, Czarny D, et al. Myopathy in severe asthma. Am Rev Respir Dis. 1992;146:517-9.